Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma

Journal of Clinical Oncology

Volumn 21, Issue 3, 2003, Pages 514-519

  Vose, Julie M ^a   Crump, M ^a   Lazarus, H ^a   Emmanouilides, C ^a   Schenkein, D ^a   Moore, J ^a   Frankel, S ^a   Flinn, I ^a   Lovelace, W ^a   Hackett, J ^a   Liang, B C ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; METHYLPREDNISOLONE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; ESAP PROTOCOL;

ARTICLE; CANCER RELAPSE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ADULT; AGED; DRUG ADMINISTRATION; FEMALE; MALE; MIDDLE AGED; PHASE 2 CLINICAL TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CYTARABINE; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; FILGRASTIM; HODGKIN DISEASE; HUMANS; INJECTIONS, SUBCUTANEOUS; LYMPHOMA, NON-HODGKIN; MALE; METHYLPREDNISOLONE; MIDDLE AGED; NEUTROPENIA; TREATMENT OUTCOME;

EID: 0037313173     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.03.040     Document Type: Article

References (26)

1. Gordon LI, Harrington D, Andersen J, et al: Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med 327:1342-1349, 1992
2. Fisher RI, Gaynor ER, Dahlberg S, et al: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 324:1002-1006, 1993
3. Velasquez WS, Cabanillas F, Salvador P, et al: Effective salvage therapy for lymphoma with cisplatin in combination with high-dose ara-C and dexamethasone (DHAP). Blood 71:117-122, 1988
4. Rodriguez MA, Cabanillas FC, Hagemeister FB, et al: W: A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas. Ann Oncol 6:609-611, 1995
5. Philip T, Guglielmi C, Hagenbeek A, et al: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333:1540-1545, 1995
6. Girouard C, Dufresne J, Imrie K, et al: Salvage chemotherapy with mini-BEAM for relapsed or refractory non-Hodgkin's lymphoma prior to autologous bone marrow transplantation. Ann Oncol 8:675-680, 1997
7. Moskowitz CH, Bertino JR, Glassman R, et al: Ifosfamide, carboplatin, and etoposide: A highly effective cytoreduction and peripheral blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol 17:3776-3785, 1999
8. Rodriguez J, Rodriguez MA, Fayad L, et al: ASHAP: A regimen for cytoreduction of refractory or recurrent Hodgkin's disease. Blood 93:3632-3636, 1999
9. Colwill R, Crump M, Couture F, et al: Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation. J Clin Oncol 13:396-402, 1995
10. Gisselbrecht C, Haioun C, Lepage E, et al: Placebo controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: Factors influencing chemotherapy administration. Leuk Lymphoma 25:289-300, 1997
11. Oliveri A, Offidani M, Ciniero L, et al: DHAP regimen plus G-CSF as salvage therapy and priming for blood progenitor cell collection in patients with poor prognosis lymphoma. Bone Marrow Transplant 16:85-93, 1995
12. Zinzani PL, Pavone E, Storti S, et al: Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma. Blood 89:1430-1436, 1997
13. Morstyn G, Foote M, Walker T, et al: Filgrastim (r-metHuG-CSF) in the 21st Century: SD/01. Acta Haematol 105:151-155, 2001
14. Lord BI, Woolford LB, Molineux GP: Kinetics of neutrophil production in normal and neutropenic animals during the response to filgrastim (r-metHu G-CSF) or filgrastim SD/01 (Peg-r-metHu G-CSF). Clin Cancer Res 7:2085-2090, 2001
15. Trillet-Lenoir V, Green J, Manegold C, et al: Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 29:319-324, 1993
16. Antman KS, Griffin JD, Elias A, et al: Effect of recombinant granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med 319:593-598, 1988
17. Crawford J, Ozer H, Stoller R, et al: Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325:164-170, 1991
18. Klimo P, Conners JM: MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med 327:1342-1346, 1985
19. Yoshida T, Nakamura S, Ohtake S, et al: Effect of granulocyte colony-stimulating factor on neutropenia due to chemotherapy for non-Hodgkin's lymphoma. Cancer 66:1904-1909, 1990
20. Velasquez WS, McLaughlin P, Tucker W, et al: ESHAP: An effective chemotherapy regimen in refractory and relapsing lymphoma. J Clin Oncol 12:1169-1176, 1994
21. Pettengell R, Gurney H, Radford JA, et al: Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: A randomized controlled trial. Blood 80:1430-1436, 1992
22. Gerhartz H, Engelhard M, Meusers P, et al: Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphoma. Blood 82:2329-2339, 1993
23. Cheung E, Cozenza M, Lopez O, et al: Modeling of r-metHuG-CSF-SD/01 mediated granulopoiesis in normal animals, with mathematical extrapolation to neutropenia settings. Blood 92:379a, 1998 (abstr 379a)
24. Johnston E, Crawford J, Blackwell S, et al: Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol 18:2522-2528, 2000
25. Green M, Koelbl H, Baselga J, et al: A randomized, double-blind, phase III study evaluating fixed-dose, once-per-cycle pegylated filgrastim (SD/01) vs daily filgrastim to support chemotherapy for breast cancer. Proc Am Soc Clin Oncol 20:90a, 2001 (abstr 90a)
26. Holmes FA, O'Shaughnessy J, Vukelja S, et al: Blinded, randomized multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 20:727-731, 2002